Table 4.
Target ID | Location | PV | SATB1 | mGluR1a | Endobiotin | CR |
---|---|---|---|---|---|---|
S31A | CA3i SO | + | + | u | + | u |
S31B | + | u | u | + | u | |
S21A | DG ML | u | u | u | − | u |
S20B | u | u | u | + | u | |
S17A | + | u | u | + | u | |
S17B | + | u | u | + | u | |
S17C | − | u | u | u | u | |
S17D | − | u | u | u | − | |
S17G | − | u | u | u | − | |
S17K | − | u | u | u | − | |
S17L | + | − | − | u | u | |
S17M | − | u | − | u | − | |
S17N | + | u | u | u | u | |
S17O | + | u | u | u | u | |
S17P | − | u | u | u | − | |
S22A | u | u | u | − | − | |
S22B | u | u | u | − | − | |
S22C | u | u | u | + | − | |
S21B | DG ML/GCL | u | u | u | − | u |
S17J | + | − | u | + | u | |
S16A | + | u | u | + | u | |
S21C | DG GCL | u | u | u | + | u |
S17H | + | u | u | u | u | |
S21F | DG GCL/PML | u | u | u | + | u |
S20A | u | u | u | + | u | |
S17F | + | u | u | + | u | |
S21D | DG PML | u | u | u | + | u |
S21E | u | u | u | − | u | |
S17E | − | u | u | (+) | − | |
S17I | + | − | u | + | u | |
Total + | 12/19 | 1/4 | 0/2 | 15/20 | 0/9 |
Molecular profiles of presumed postsynaptic neurons based on close apposition of axon terminals. Additional tests: targets S20A and S20B were also M2R−; S31A was SOM+; S22A and S22B were nNOS+ and S22C was nNOS−.
+, Detectable positive immunoreactivity or signal; −, undetectable immunoreactivity or signal in vicinity of immunopositive signals; u, unknown (unavailable or inconclusive). Parentheses indicate weak immunoreactivity or signal. Endobiotin, high levels of endogenous intracellular biotin.